Radical cystectomy (RC) with pelvic lymphadenectomy remains the standard treatment for patients with localised muscle-invasive bladder cancer (MIBC) and for BCG-refractory non-muscle invasive bladder cancer (NMIBC; [@bib6]). Unfortunately, 10-year cancer-specific survival (CSS) rates are only ∼70% ([@bib7]) and 40--60% ([@bib26]; [@bib24]) for high-risk NMIBC and for MIBC, respectively. More aggressive approaches can be used to improve oncological outcomes, namely neo-adjuvant or adjuvant chemotherapy for patients with MIBC ([@bib12]), and early RC for patients with high-risk NMIBC ([@bib18]). However, the non-selective use of these approaches carries the risk of overtreatment, particularly among patients with favourable prognoses. Treatment decision-making is oftentimes challenging, particularly because risk stratification based on clinical and pathologic parameters is insufficient ([@bib25]; [@bib5]).

Peripheral neutrophil--lymphocyte ratio (NLR) is a novel prognostic biomarker in bladder cancer (BC). Elevated NLR has been shown to be predictive of adverse oncologic outcomes in patients with NMIBC ([@bib4]; [@bib16]; [@bib20]) and MIBC ([@bib10]; [@bib17]; [@bib15]; [@bib22]; [@bib29]). Several other complete blood count (CBC)-based prognostic biomarkers have also been described for BC, including absolute platelet count ([@bib4]; [@bib28]; [@bib21]), haemoglobin, ([@bib10]; [@bib9]), and lymphocyte--monocyte ratio (LMR; [@bib27]). In addition, platelet--lymphocyte ratio (PLR) has also shown to predict oncologic outcomes for other cancer sites ([@bib1]; [@bib8]), but studies of its prognostic value in BC have yet to be reported.

There is likely some degree of overlap between these CBC-based biomarkers, and some may be redundant. For future studies and potential clinical use, a parsimonious combination of these biomarkers is required. Our objective was thus to determine which combination of these biomarkers most efficiently predicts oncologic outcomes in patients undergoing RC for BC.

Materials and Methods
=====================

Patients and data collection
----------------------------

We performed a retrospective cohort study of patients undergoing RC for urothelial carcinoma of the bladder identified using our institutional database (1992--2012), which has been described in detail in prior reports ([@bib2]; [@bib15]). Institutional research ethics approval was obtained. Clinical and pathologic data were obtained using chart review. Mortality data were obtained using the Princess Margaret Hospital Cancer Registry. Exclusion criteria were unavailable CBCs and differentials (*n*=20), history of conditions that could potentially affect blood cell lines (leukemia: *n*=2, human immunodeficiency virus infection: *n*=1, malignant lymphoma: *n*=3, connective tissue disease: *n*=4) and RC done for salvage following failed chemo-radiation (*n*=20).

Primary study exposure
----------------------

The date of treatment initiation was defined as the date of RC or date of initiation of neo-adjuvant chemotherapy, as applicable. Complete blood count collections were performed usually a week before treatment initiation (median of 6 days, IQR=2--10 days) as part of the routine pre-treatment clinical assessment. Clinical notes were reviewed to rule out any symptoms or signs of infection around the time of CBCs.

Candidate biomarkers considered in our study included haemoglobin, individual cell counts (absolute neutrophil, lymphocyte, monocyte, and platelet counts), and the cell count ratios NLR, monocyte--lymphocyte ratio, LMR, and PLR.

Clinical follow-up and outcomes
-------------------------------

Patients were generally seen in follow-up ∼6--8 weeks following discharge, and every 3--6 months thereafter for physical examination and imaging to assess for hydronephrosis and cancer recurrence. Visits were further spaced apart over time based on individual physician\'s practice patterns and clinical suspicion. The study outcomes were recurrence-free (RFS), CSS, and overall survival (OS) from time of treatment initiation. Patients were censored if event-free at their most recent clinic visit, up to 31 October 2013.

Statistical analysis
--------------------

Descriptive statistics were used to summarise cohort characteristics and distributions of CBC-based predictors. Complete blood count-based predictors with skewed distributions were log-transformed to improve model fit.

An initial assessment of CBC-based predictors was performed using univariate time-dependent receiver operating characteristics (ROC) curves for each outcome measure at 12-month intervals for 5 years ([@bib14]). To avoid issues with multi-collinearity in ensuing analytic steps, similar predictors were compared and only those with superior areas under the ROC curves were retained for further evaluation.

For each of the retained predictors, Kaplan--Meier analyses with the log-rank test and univariate Cox regression analyses were performed in order to confirm the predictive value seen in other studies ([@bib4]; [@bib10]; [@bib28]; [@bib1]; [@bib17]; [@bib8]; [@bib15]; [@bib21]; [@bib22]; [@bib27]; [@bib29]; [@bib9]; [@bib20]).

Next, we created multivariable Cox proportional hazards models considering all possible combinations of the retained CBC-based predictors and clinical parameters (age, gender, heavy smoking status defined as ⩾30 pack-years, Charlson co-morbidity index, hydronephrosis, concurrent carcinoma *in situ*, pathological T-stage, and pathological N-stage, lymphovascular invasion (LVI) and positive surgical margin status). A robust sandwich covariance matrix estimator was used to account for clustering of outcomes by surgeon ([@bib19]). Optimal models were selected as those that minimised the Akaike Information Criterion (AIC), representing parsimonious models that offered the best fit to the data with the fewest number of predictors. The partial log-likelihood test was used to compare final predictive models with and without the selected CBC-based predictors to determine if these predictors significantly improved model fit.

Statistical analyses were performed using SAS v9.3 (SAS Institute Inc, Cary, NC, USA). All tests were two-sided with *P*-values \<0.05 considered statistically significant.

Results
=======

The final cohort included 418 patients with a median age of 70 years (IQR=61--76 years). Pathological extra-vesical extension was present in 191 patients (46%), and nodal metastases were present in 115 patients (27%). Cohort characteristics are further described in [Table 1](#tbl1){ref-type="table"}. During a median follow-up of 40 months (IQR=14--72 months), there were 136 cancer recurrences, 107 BC-related deaths, and 177 deaths overall.

The AUCs of the time-dependent ROC curve analyses, used to identify the best predictors among those that are similar to each other, are shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. The AUCs for NLR were superior to those for absolute neutrophil and lymphocyte counts, whereas the AUCs for PLR were superior to those for absolute platelet and lymphocyte counts. The AUCs for LMR were superior to those for monocyte--lymphocyte ratio, absolute monocyte count and absolute lymphocyte count. There were no predictors similar to haemoglobin. Thus, in subsequent analyses, only haemoglobin, NLR, LMR, and PLR were retained, whereas those predictors deemed similar and inferior were eliminated in order to avoid collinearity.

In Kaplan--Meier analyses, higher NLR and PLR values (above median), and lower haemoglobin and LMR values (below median) were shown to be associated with worse RFS, CSS, and OS (all *P*\<0.05, except for the association between haemoglobin and RFS where *P*=0.08; see [Figure 1](#fig1){ref-type="fig"}). These findings were replicated in the univariate Cox-regression analyses ([Table 2](#tbl2){ref-type="table"}). Increasing NLR was associated with worse RFS (HR per 1-log unit=1.49, 95% CI=1.22--1.81, *P*\<0.001), CSS (HR per 1-log unit=1.58, 95% CI=1.32--1.90, *P*\<0.001), and OS (HR per 1-log unit=1.74, 95% CI=1.43--2.11, *P*\<0.001). Increasing PLR was also associated with worse RFS, CSS, and OS. Increasing haemoglobin level was associated with improved RFS (HR per 1 g/dl=0.90, 95% CI=0.86--0.94, *P*\<0.001), CSS (HR per 1 g/dl=0.87, 95%CI=0.82--0.91, *P*\<0.001), and OS (HR per 1 g/dl=0.84, 95% CI=0.82--0.87, *P*\<0.001). Increasing LMR was also associated with better RFS, CSS, and OS.

Final parsimonious multivariable models, created based on minimising AIC values, are shown in [Table 3](#tbl3){ref-type="table"}. NLR (HR per 1-log unit=1.52, 95% CI=1.17--1.98, *P*=0.002) was the only CBC-based predictor retained for inclusion in the model for RFS, along with T-stage, N-stage, LVI, and positive surgical margins. NLR (HR per 1-log unit=1.47, 95% CI=1.20--1.80, *P*\<0.001) and haemoglobin (HR per 1 g/dl=0.91, 95% CI=0.86--0.95, *P*\<0.001) were the only CBC-based predictors retained in the model for CSS, along with T-stage, N-stage, LVI, and positive surgical margins. Last, NLR (HR per 1-log unit HR=1.56, 95% CI=1.16--2.10, *P*=0.004) and haemoglobin (HR per 1 g/dl=0.90, 95% CI=0.88--0.93, *P*\<0.001) were the only CBC-based predictors retained in the model for OS, along with age, Charlson co-morbidity index, T-stage, N-stage, LVI, and positive surgical margins.

Upon comparing final models with and without the selected CBC-based predictors, it was found that the inclusion of NLR significantly improved the goodness-of-fit of the model for RFS (*P*=0.014), whereas the inclusion of NLR and haemoglobin significantly improved the goodness-of-fit of the models for CSS (*P*=0.008) and OS (*P*\<0.001), compared with respective models with clinical and pathologic parameters only (see [Supplementary Table 2 for details](#sup1){ref-type="supplementary-material"}).

Discussion
==========

Although the potential role of inflammation in cancer was originally proposed by Rudolph Virchow in the nineteenth century, it is only during the past 10--15 years that a deeper understanding has emerged of the impact of inflammation in carcinogenesis and cancer progression ([@bib11]; [@bib13]). Recently, there has been growing interest in using CBC-based measures as BC biomarkers, with numerous studies separately reporting on the impact of individual components of the CBC on RC outcomes ([@bib4]; [@bib10]; [@bib28]; [@bib1]; [@bib17]; [@bib8]; [@bib15]; [@bib21]; [@bib22]; [@bib27]; [@bib29]; [@bib9]). With growing data supporting the prognostic value of various CBC-based biomarkers, we sought to elucidate which of these variables would ultimately possess the greatest potential in the RC population.

In our study, NLR was the sole CBC-derived biomarker to be independently predictive of RFS, CSS, and OS. This is consistent with existing literature, with NLR being the most frequently reported CBC-derived biomarker in BC ([@bib4]; [@bib10]; [@bib17]; [@bib15]; [@bib16]; [@bib22]; [@bib29]; [@bib20]). NLR has been shown to predict muscle-invasion upon transurethral resection ([@bib4]; [@bib16]), recurrence, and progression for NMIBC ([@bib20]), upstaging at the time of RC ([@bib17]; [@bib15]; [@bib22]; [@bib29]), and worse oncologic outcomes following RC ([@bib10]; [@bib17]; [@bib15]; [@bib29]).

NLR also has a strong biological rationale, in the context of the role of immunity and inflammation in cancer development and progression ([@bib11]; [@bib13]). Conceptually, NLR represents the ratio of the innate immune response (i.e., neutrophils) to the adaptive immune response (i.e., lymphocytes). Neutrophils assemble at the margins of pre-malignant lesions and promote carcinogenesis through various mechanisms, including: (i) producing reactive oxygen species capable of inducing DNA damage and genomic instability, (ii) promoting the secretion of various growth factors that enhance the proliferation of mutated cells, (iii) promoting angiogenesis, and (iv) promoting metastasis ([@bib11]). Meanwhile, T and B lymphocytes are capable of recognising tumour antigens and may aid in an anti-tumour response through cell-mediated and antibody-dependent cytotoxicity, respectively, although in the majority of cases, this response alone is insufficient to restrain tumour growth ([@bib11]). In our study, circulating NLR had greater predictive value than either absolute neutrophil or lymphocyte counts alone, suggesting that both counts are important and that the ratio is the most informative.

Haemoglobin level also added predictive value for CSS and OS, independently of NLR and other clinic-pathologic predictors. Anaemia has been shown to be associated with worse RFS, CSS, and OS following RC ([@bib9]). Anaemia is likely multifactorial in this population. It may be in part due to blood loss from tumour-related bleeding. There may also be a component of anaemia of chronic disease (also known as anemia of chronic inflammation), which is driven by acute and/or chronic immune system activation ([@bib30]), and in turn may be a systemic effect of BC or of other co-morbid diseases.

Secondary thrombocytosis (also called reactive thrombocytosis) is most often the result of acute or chronic inflammatory conditions, infections, or malignancies. This is mediated by pro-inflammatory cytokines such as interleukin (IL)-1, IL-6, IL-11, and tumour necrosis factor-*α*, among others ([@bib3]). In patients undergoing RC, platelet count was associated with more advanced disease ([@bib21]) and worse CSS ([@bib28]). In our study, PLR, compared with absolute platelet counts, showed greater discrimination for oncologic outcomes following RC. Moreover, we demonstrated for the first time, the potential ability of PLR as a prognostic indicator for RC. However, PLR did not add value to multivariable models when NLR, haemoglobin level, and clinical predictors were included.

Similar to neutrophils, macrophages (differentiated monocytes) can support tumour-related angiogenesis and cell migration ([@bib27]). Lower lymphocyte--monocyte ratio (LMR) was demonstrated in one study ([@bib27]) to be associated with reduced disease-free survival and OS. The Kaplan--Meier analyses in our study are consistent with this finding. However, as was the case for PLR, LMR was not retained as an independent predictor of oncologic outcomes once other variable were considered.

To our knowledge, the present study is the first to compare various CBC-based biomarkers in order to determine which parsimonious combination most efficiently predicts oncologic outcomes in BC. Now that it is more clear which predictors are most efficient, it is possible to formally evaluate how NLR and haemoglobin can best be employed to guide clinical decision-making.

Data supporting a potential clinical role for CBC-based predictors, particularly NLR, are emerging. For example, NLR can risk-stratify patients with clinical NMIBC into a group with excellent outcomes upon early cystectomy (\>90% 5-years CSS) and a group with similar oncologic outcomes to patients with clinical MIBC (∼60% 5-year CSS; [@bib15]). This may be helpful in guiding the use of early cystectomy. Also, change in NLR during neo-adjuvant chemotherapy can be helpful in predicting pathological response ([@bib23]). Last, NLR can also further risk-stratify patients beyond pathological stage, which may be helpful in guiding the use of adjuvant chemotherapy ([@bib15]).

Our study is not without limitations. First, this is a single-institution retrospective observational study. Second, we did not routinely measure CBCs at regular intervals post-RC, and therefore cannot comment on whether changes in CBC-based biomarkers have predictive value. Given the myriad factors that can affect CBC levels postoperatively, it is unlikely that immediate post-RC CBC components will yield prognostic value. Third, our cohort included very few patients receiving neo-adjuvant chemotherapy, and therefore further studies are needed to evaluate how CBC-based biomarkers are affected by neo-adjuvant chemotherapy, and whether CBC-based biomarkers can predict response to neo-adjuvant chemotherapy. Fourth, data C-reactive protein-levels were not available in our retrospective cohort. Future studies are warranted to evaluate if C-reactive protein provides additional prognostic value to NLR and haemoglobin levels. Last, it is unclear whether our findings in patients undergoing RC are generalisable to all BC patients. Further studies are warranted in patients with low-intermediate risk NMIBC.

Conclusion
==========

Several CBC-based biomarkers are reported to have prognostic value in BC. They are cost-effective and widely accessible. Our study has identified NLR as the most efficient marker for predicting RFS, whereas NLR and haemoglobin together were found to be the most efficient for predicting CSS and OS. These predictors can be helpful along with other known predictors such as clinical and pathologic stage and grade. It is not practical for clinicians to use redundant biomarkers, and parsimony is essential. This study hopes to guide the focus of future research on CBC-based predictors. Further studies should be directed at how NLR and haemoglobin can help guide clinical decision-making in this complex patient population.
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###### Cohort characteristics

  **Cohort characteristics**                                      **Total** ***n*****=418**
  -------------------------------------------------------------- ---------------------------
  **Patient characteristics**                                    
  Age in years, median (IQR)                                             70 (61--76)
  Female sex, *n* (%)                                                     96 (23.0)
  Heavy smoking (⩾30pack-years), *n* (%)                                  133 (32)
  BMI (kg/m^2^), median (IQR)                                            27 (24--30)
  Charlson co-morbidity index, median (IQR)                               1 (0--2)
  **Disease characteristics**                                    
  Hydronephrosis, *n* (%)                                                 117 (28)
  Concurrent CIS, *n* (%)                                                 188 (45)
  **T-stage, *n* (%)**                                                         
   pT0                                                                     25 (6)
   pTa/Tis/T1/T2                                                          202 (48)
   pT3/T4                                                                 191 (46)
  **N-stage, *n* (%)**                                                         
   pN0                                                                    282 (68)
   pN+                                                                    115 (27)
   pNx                                                                     21 (5)
  Lymphovascular invasion, *n* (%)                                        141 (34)
  Positive surgical margin[a](#t1-fn2){ref-type="fn"}, *n* (%)             33 (8)
  **Other treatment characteristics**                            
  **Year of surgery, *n* (%)**                                                 
   1992--2005                                                             208 (50)
   2006--2012                                                             210 (50)
  Continent diversion, *n* (%)                                             89 (21)
  Node total, median (IQR)                                               12 (7--19)
  Neo-adjuvant chemotherapy, *n* (%)                                       28 (7)
  Adjuvant chemotherapy*, n* (%)                                           87 (20)
  Salvage chemotherapy, *n* (%)                                            54 (13)
  **CBC-based parameters**                                       
  Haemoglobin (g/dl), median (IQR)                                    13.2 (11.6--14.5)
  WBC (× 10^9^/l), median (IQR)                                        7.6 (6.0--9.1)
  Neutrophils (× 10^9^/l), median (IQR)                                4.8 (3.8--6.5)
  Monocytes (× 10^9^/l), median (IQR)                                  0.6 (0.5--0.7)
  Lymphocytes (× 10^9^/l), median (IQR)                                1.7 (1.3--2.1)
  Platelets (× 10^9^/l), median (IQR)                                  253 (204--303)
  NLR, median (IQR)                                                    2.9 (2.1--4.3)
  MLR, median (IQR)                                                   0.36 (0.26--0.50)
  LMR, median (IQR)                                                    2.8 (2.0--3.8)
  PLR, median (IQR)                                                    150 (103--202)

Abbreviations: BMI=body mass index; CBC=complete blood count; CIS=carcinoma *in situ*; IQR=interquartile range; LMR=lymphocyte monocyte ratio; MLR=monocyte lymphocyte ratio; NLR=neutrophil lymphocyte ratio; PLR=platelet lymphocyte ratio; WBC=white blood cell count.

Positive surgical margins rates are based on permanent sections (paraffin-embedded) and exclude ureteral carcinoma *in-situ*.

###### Univariate associations between predictors and oncologic outcomes following radical cystectomy

                                                                            **Recurrence-free survival**    **Cancer-specific survival**  **Overall survival**                                 
  ------------------------------------------------------------------------- ------------------------------ ------------------------------ ---------------------- --------- ------------------- ---------
  Haemoglobin, per 1 g/dl                                                   0.90 (0.86--0.94)                         \<0.001             0.87 (0.82--0.91)       \<0.001  0.84 (0.82--0.87)    \<0.001
  Neutrophil--lymphocyte ratio, per 1-log unit[a](#t2-fn2){ref-type="fn"}   1.49 (1.22--1.81)                         \<0.001             1.58 (1.32--1.90)       \<0.001  1.74 (1.43--2.11)    \<0.001
  Lymphocyte--monocyte ratio, per 1-log unit[a](#t2-fn2){ref-type="fn"}     0.66 (0.55--0.79)                         \<0.001             0.69 (0.53--0.91)        0.009   0.70 (0.55--0.88)     0.002
  Platelet--lymphocyte ratio, per 100 units                                 1.22 (1.08--1.38)                          0.002              1.21 (1.05--1.41)        0.01    1.16 (1.02--1.33)     0.03

Abbreviations: CI=confidence interval; HR=hazard ratio.

Log-transformed.

###### Final parsimonious multivariable models for recurrence-free, cancer-specific, and overall survival

  **Parameter**                                                                    **HR (95% CI)**    ***P-*****value**
  ------------------------------------------------------------------------------ ------------------- -------------------
  **Model for recurrence-free survival**[a](#t3-fn2){ref-type="fn"}                                  
  T-stage, pT3-4 *vs* pT0-2                                                       1.58 (1.03--2.42)         0.03
  N-stage, N+ *vs* N0                                                             2.15 (2.82--2.53)       \<0.0001
  Lymphovascular invasion                                                         1.72 (1.04--2.86)         0.03
  Positive surgical margin                                                        2.16 (1.42--3.28)        \<0.001
  Neutrophil--lymphocyte ratio, per 1-unit increase[b](#t3-fn3){ref-type="fn"}    1.52 (1.17--1.98)         0.002
  **Model for cancer-specific survival**[c](#t3-fn4){ref-type="fn"}                                  
  T-stage, pT3-4 *vs* pT0-2                                                       1.67 (1.07--2.62)         0.02
  N-stage, N+ *vs* N0                                                             2.13 (1.27--3.57)         0.004
  Lymphovascular invasion                                                         1.75 (0.94--3.28)         0.08
  Positive surgical margin                                                        1.82 (0.88--3.79)         0.11
  Haemoglobin (per 1 g/l increase)                                                0.91 (0.86--0.95)        \<0.001
  Neutrophil--lymphocyte ratio, per 1-unit increase[b](#t3-fn3){ref-type="fn"}    1.47 (1.20--1.80)        \<0.001
  **Model for overall survival**[d](#t3-fn5){ref-type="fn"}                                          
  Age, per 1 year increase                                                        1.03 (1.01--1.04)         0.008
  Charlson co-morbidity index, per 1-point increase                               1.16 (1.03--1.32)         0.01
  T-stage, pT3-4 *vs* pT0-2                                                       1.42 (0.83--2.45)         0.20
  N-stage, N+ *vs* N0                                                             1.55 (1.12--2.14)         0.008
  Lymphovascular invasion                                                         1.74 (1.03--2.93)         0.04
  Positive surgical margin                                                        1.86 (0.90--3.82)         0.09
  Haemoglobin, per 1 g/dl increase                                                0.90 (0.88--0.93)        \<0.001
  Neutrophil--lymphocyte ratio, per 1-unit increase[b](#t3-fn3){ref-type="fn"}    1.56 (1.16--2.10)         0.004

Abbreviations: AIC=Akaike Information Criterion; CI=confidence interval; HR=hazard ratio.

Likelihood ratio omnibus test: *χ*^2^=84.8, dF=5, *P*\<0.001; AIC=1407.0.

Variable was log-transformed, and therefore hazard ratios represent effect per 1 log-unit.

Likelihood ratio omnibus test: *χ*^2^=68.9, dF=6, *P*\<0.001; AIC=1101.6.

Likelihood ratio omnibus test: *χ*^2^=111.0, dF=8, *P*\<0.001; AIC=1780.7.
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